Nanotechnology and atherosclerosis imaging: Emerging diagnostic and therapeutic applications

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 2, 2008, Pages 98-104

  Schoenhagen, Paul ^a,b   Conyers, Jodie L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Atherosclerosis imaging; Intravascular ultrasound; Multidetector computed tomography; Nanotechnology; Prevention; Vulnerable plaque

Indexed keywords

ANTILIPEMIC AGENT; BIOLOGICAL MARKER; NANOPARTICLE; PIOGLITAZONE; RIMONABANT; CARDIOVASCULAR AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG CARRIER;

ATHEROGENESIS; ATHEROSCLEROSIS; BIOENGINEERING; CARDIOVASCULAR DISEASE; CELL STRUCTURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; HUMAN; MOLECULAR IMAGING; MORTALITY; NANOTECHNOLOGY; NONHUMAN; PATENT; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; ANGIOCARDIOGRAPHY; ANIMAL; COMPUTER ASSISTED TOMOGRAPHY; MAGNETIC RESONANCE ANGIOGRAPHY; MASS COMMUNICATION; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; CARDIOVASCULAR AGENTS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DIFFUSION OF INNOVATION; DRUG CARRIERS; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; NANOPARTICLES; NANOTECHNOLOGY; PATENTS AS TOPIC; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 51149115569     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008784705377     Document Type: Review

References (144)

1. American Heart Association. Heart and Stroke Statistics. 2004 Update. Dallas, TX: American Heart Association. © 2004, available at www.americanheart.org.
2. Hasdai D, Behar S, Wallentin L, et al. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23: 1190-1201.
3. World Health Organization. The Atlas of Heart Disease and Stroke. Edited by J. Mackay and G. Mensah. 2004; ISBN 9241562765.
4. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488.
5. Damani SB, Topol EJ. Future use of genomics in coronary artery disease. J Am Coll Cardiol 2007; 50: 1933-1940.
6. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from pathobiological determinants of atherosclerosis in youth study. JAMA 1999; 281: 727-735.
7. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound. Circulation 2001; 103: 2705-2710.
8. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-1353.
9. Schoenhagen P, Ziada KM, Vince DG, Nissen SE, Tuzcu EM. Arterial remodeling and coronary artery disease: The concept of "dilated" versus "obstructive" coronary atherosclerosis. J Am Coll Cardiol 2001; 38: 297-306.
10. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-1282.
11. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002; 105: 939-943.
12. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 2002; 105: 297-303.
13. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable and unstable coronary syndromes. Circulation 2000; 101: 598-603.
14. Schoenhagen P, Vince DG, Ziada KM, et al. Relation of matrix-metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. Am J Cardiol 2002; 89: 1354-1359.
15. Pasterkamp G, Schoneveld AH, van der Wal AC, et al. Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: The remodeling paradox. J Am Coll Cardiol 1998; 32: 655-662.
16. Ivan E, Khatri JJ, Johnson C, et al. Expansive arterial remodeling is associated with increased neointimal macrophage foam cell content: The murine model of macrophage-rich carotid artery lesions. Circulation 2002; 105: 2686-2691.
17. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
18. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.
19. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
20. Williams H, Johnson JL, Carson KGS, Jackson CL. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2002; 22: 788-792.
21. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12.
22. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: A three-vessel intravascular ultrasound study. Circulation 2002; 106: 804-808.
23. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915-922.
24. Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: An angioscopic study. J Am Coll Cardiol 2001; 37: 1284-1288.
25. Schoenhagen P, Stone GW, Nissen SE, et al. Coronary plaque morphology and frequency of ulceration distant from culprit lesions in patients with unstable and stable presentation. Arterioscler Thromb Vasc Biol 2003; 23: 1895-1900.
26. Wang L, Fan C, Topol SE, Topol EJ, Wang Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 2003; 302: 1578-1581.
27. Chen M, Capps C, Willerson JT, Zoldhelyi P. E2F-1 regulates nuclear factor-kappaB activity and cell adhesion: Potential antiinflammatory activity of the transcription factor E2F-1. Circulation 2002; 106: 2707-2713.
28. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res 2001; 89: 305-316.
29. Tuzcu EM, Schoenhagen P. Acute coronary syndromes, plaque vulnerability, and carotid artery disease: The changing role of atherosclerosis imaging. J Am Coll Cardiol 2003; 42: 1033-1036.
30. Fayad ZA, Fuster V, Nikolaou K, Becker C. Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: Current and potential future concepts. Circulation 2002; 106: 2026-2034.
31. MacNeill BD, Lowe HC, Takano M, Fuster V, Jang IK. Intravascular modalities for detection of vulnerable plaque: Current status. Arterioscler Thromb Vasc Biol 2003; 23(8): 1333-1342.
32. Sankatsing RR, de Groot E, Jukema JW, et al. Surrogate markers for atherosclerotic disease. Curr Opin Lipidol 2005; 16: 434-441.
33. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Reversal investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004; 29: 1071-1080.
34. Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001; 104: 387-392.
35. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
36. Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006; 295: 1556-1565.
37. Schoenhagen P, Tuzcu EM, Apperson-Hansen C, et al. Determinants of arterial wall remodeling during lipid-lowering therapy: Serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation 2006; 113: 2826-2834.
38. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508:
39. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290: 2292-2300.
40. Tardif JC, Grěgoire J, L'Allier PL, et al. Effects of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 2007; 297: 1675-1682.
41. Tardif JC, Grégoire J, L'Allier PL, et al. Avasimibe and progression of lesions on ultrasound (A-PLUS) investigators. Effects of the acyl coenzyme A: Cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004; 110: 3372-3377.
42. Nissen SE, Tuzcu EM, Brewer HB, et al. ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006; 354: 1253-1263.
43. Nissen SE, Tardif JC, Nicholls SJ, et al. ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-1316.
44. Nissen SE, Tuzcu EM, Libby P, et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary diseAse and normal blood pressure: The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2225.
45. Sipahi I, Tuzcu EM, Schoenhagen P, et al. Effects of normal, prehypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006; 48: 833-838.
46. Sipahi I, Tuzcu EM, Wolski KE, et al. Beta-blockers and progression of coronary atherosclerosis: Pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 2007; 147: 10-18.
47. Schoenhagen P, Nissen SE. Coronary atherosclerotic disease burden: An emerging endpoint in progression/regression studies using intravascular ultrasound. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3: 218-226.
48. Taylor AJ, Kent SM, Flaherty PJ, et al. Arbiter: Arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055-2060.
49. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
50. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
51. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-1604.
52. Kawasaki M, Takatsu H, Noda T, et al. Noninvasive quantitative tissue characterization and two-dimensional color-coded map of human atherosclerotic lesions using ultrasound integrated backscatter: comparison between histology and integrated backscatter images. J Am Coll Cardiol 2001; 38: 486-492.
53. Takiuchi S, Rakugi H, Honda K, et al. Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. Circulation 2000; 102: 766-770.
54. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002; 106: 2200-2206.
55. Stahr PM, Hofflinghaus T, Voigtlander T, et al. Discrimination of early/intermediate and advanced/complicated coronary plaque types by radiofrequency intravascular ultrasound analysis. Am J Cardiol 2002; 90: 19-23.
56. De Korte CL, Pasterkamp G, Van der Steen AF, Woutman HA, Bom N. Characterization of plaque components with intravascular ultrasound elastography in human femoral and coronary arteries in vitro. Circulation 2000; 102: 617-623.
57. Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation 2002; 106: 1640-1645.
58. Guillermo JT, Yabushita H, Houser SL, et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation 2003; 107: 113-119.
59. Casscells W, Hathorn B, David M, et al. Thermal detection of cellular infiltrates in living atherosclerotic plaques: Possible implications for plaque rupture and thrombosis. Lancet 1996; 347: 1447-1451.
60. Stefanadis C, Diamantopoulos L, Vlachopoulos C, et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: A new method of detection by application of a special thermography catheter. Circulation 1999; 99: 1965-1971.
61. Toutouzas K, Synetos A, Stefanadi E, et al. Correlation between morphologic characteristics and local temperature differences in culprit lesions of patients with symptomatic coronary artery disease. J Am Coll Cardiol 2007; 49: 2264-2271.
62. Schoenhagen P. Plaque temperature, arterial remodeling, and inflammation: Understanding "hot-spots" in the coronary arteries. J Am Coll Cardiol 2007; 49: 2272-2273.
63. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110(23): 3512-3517.
64. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104: 249-252.
65. De Groot E, Jukema JW, Montauben van Swijndregt AD, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlation with coronary arteriogarphic findings: A report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998; 31: 1561-1567.
66. MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID Atherosclerosis Substudy. Circulation 1998; 97: 1784-1790.
67. Rudd JHF, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002; 105: 2708-2711.
68. Lederman RJ, Raylman RR, Fisher SJ, et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun 2001; 22: 747-753.
69. Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 2002; 106: 1368-1373.
70. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI. Arterioscler Thromb Vasc Biol 2001; 21: 1623-1629.
71. Kim WY, Stuber M, Bornert P, Kissinger KV, Manning WJ, Botnar RM. Three-dimensional black-blood cardiac magnetic resonance coronary vessel wall imaging detects positive arterial remo-deling in patients with nonsignificant coronary artery disease. Circulation 2002; 106: 296-299
72. Schroeder S, Kopp AF, Baumbach A, et al. Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. J Am Coll Cardiol 2001; 37: 1430-1435.
73. Leber AW, Knez A, Becker A, et al. Accuracy of multidetector spiral computed tomography in identifying and differentiating the composition of coronary atherosclerotic plaques: A comparative study with intracoronary ultrasound. J Am Coll Cardiol 2004; 43: 1241-1247.
74. Schoenhagen P, Tuzcu EM, Stillman AE, et al. Non-invasive assessment of plaque morphology and remodeling in mildly stenotic coronary segments: Comparison of 16-slice computed tomography and intravascular ultrasound. Coron Artery Dis 2003; 14: 459-462.
75. Achenbach S, Moselewski F, Ropers D, et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: A segment-based comparison with intravascular ultrasound. Circulation 2004; 109: 14-17.
76. Halliburton SS, Schoenhagen P, Nair A, et al. Contrast enhancement of coronary atherosclerotic plaque: A high-resolution, multidetector-row computed tomography study of pressure-perfused, human ex vivo coronary arteries. Coron Artery Dis 2006; 17: 553-560.
77. Mulder WJ, Strijkers GJ, Vucic E, Cormode DP, Nicolay K, Fayad ZA. Magnetic resonance molecular imaging contrast agents and their application in atherosclerosis. Top Magn Reson Imaging 2007; 18: 409-417.
78. Briley-Saebo KC, Mulder WJ, Main V, et al. Magnetic resonance imaging of vulnerable atherosclerotic plaques: Current imaging strategies and molecular imaging probes. J Magn Reson Imaging 2007; 26: 460-479.
79. Rudd JH, Myers KS, Bansilal S, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007; 50: 892-896.
80. Weissleder R. Scaling down imaging: Molecular mapping of cancer in mice. Nat Rev Cancer 2002; 2: 11-18.
81. Hogemann D, Basilion JP. "Seeing inside the body": MR imaging of gene expression. Eur J Nucl Med Mol Imaging 2002; 29: 400-408.
82. Blankenberg FG, Strauss HW. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging 2002; 16: 352-361.
83. Feldkamp LA, Goldstein SA, Parfitt AM, Jesion G, Kleerekoper M. The direct examination of three-dimensional bone architecture in vitro by computed tomography. J Bone Miner Res 1989; 4: 3-11.
84. Muller R, Van Campenhout H, Van Damme B, et al. Morphometric analysis of human bone biopsies: A quantitative structural comparison of histological sections and micro-computed tomography. Bone 1998; 23: 59-66.
85. Flannery BP, Deckman WG, Roberge WG, D'Amico KL. Three dimensional x-ray microtomography. Science 1987; 273: 1439-1444.
86. Hoddad WS, McNulty I, Trebes JE, Anderson EH, Lernque RA, Yang L. Ultrahigh resolution x-ray tomography. Science 1994; 2: 1213-1215.
87. Dover SD, Elliott JC, Boakes R, Bowen DK. Three-dimensional x-ray microscopy with accurate registration of tomographic sections. J Microsc 1989; 153: 187-191.
88. Cavanaugh D, Johnson E, Price RE, Kurie J, Travis EL, Cody DD. in vivo Respiratory-gated micro-CT imaging in small-animal oncology models. Mol Imaging 2004; 3: 55-62.
89. Jorgensen SM, Demirkaya O, Ritman EL. Three-dimensional imaging of vasculature and parenchyma in intact rodent organs with x-ray micro-CT. Am J Physiol 1998; 275: H1103-H1114.
90. Rodriguez-Porel M, Lerman A, Ritman EL, Wilson S, Best PJ, Lerman LO. Altered myocardial microvasculature 3D architecture in experimental hypercholesterolemia. Circulation 2000; 102: 2028-2030.
91. Mohlenkamp S, Bebrenbeck TR, Lerman A, et al. Coronary microvascular functional reserve: Quantification of long-term changes with electron-beam CT preliminary results in a porcine model. Radiology 2001; 221: 229-236.
92. Lerman A, Ritman EL. Evaluation of microvascular anatomy by micro-CT. Herz 1999; 24: 531-533.
93. Garcia-Sanz A, Rodriguez-Barbero A, Bentley MD, Ritman EL, Romero JC. Three-dimensional microcomputed tomography of renal vasculature in rats. Hypertension 1998; 31: 440-444.
94. Kwon HM, Sangiorgi G, Ritman EL, et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998; 101: 1551-1556.
95. Wan SY, Kiraly AP, Ritman EL, Higgins WE. Extraction of the hepatic vasculature in rats using 3-D micro-CT images. IEEE Trans Med Imaging 2000; 19: 964-971.
96. Kantor B, Jorgensen SM, Lund PE, Chmelik MS, Reyes DA, Ritman EL. Cryostatic micro-computed tomography imaging of arterial wall perfusion. Scanning 2002; 24: 186-190.
97. Zhu XY, Rodriguez-Porcel M, Bentley MD, et al. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation 2004; 109: 2109-2115.
98. Wilson SH, Herrmann J, Lerman LO, et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002; 105: 415-418.
99. Langheinrich AC, Michniewicz A, Bohle RM, Ritman EL. Vasa vasorum neovascularization and lesion distribution among different vascular beds in ApoE-/-/LDL-/- double knockout mice. Atherosclerosis 2007; 191: 73-81.
100. Langheinrich AC, Michniewicz A, Sedding DG, et al. Correlation of vasa vasorum neovascularization and plaque progression in aortas of apolipoprotein E(-/-)/low-density lipoprotein(-/-) double knockout mice. Arterioscler Thromb Vasc Biol 2006; 26: 347-352.
101. Langheinrich AC, Bohle RM, Greschus S, et al. Atherosclerotic lesions at micro CT: Feasibility for analysis of coronary artery wall in autopsy specimens. Radiology 2004; 231: 675-681.
102. Li Y, Shawgo RS, Tyler B, et al. in vivo Release from a drug delivery MEMS device. J Control Release 2004; 100: 211-219.
103. Wu LQ, Payne GF. Biofabrication: Using biological materials and biocatalysts to construct nanostructured assemblies. Trends Biotechnol 2004; 22: 593-599.
104. Hsiai TK, Cho SK, Wong PK, et al. Micro sensors: Linking real-time oscillatory shear stress with vascular inflammatory responses. Ann Biomed Eng 2004; 32: 189-201.
105. Weisenberg BA, Mooradian DL. Hemocompatibility of materials used in microelectromechanical systems: Platelet adhesion and morphology in vitro. J Biomed Mater Res 2002; 60: 283-291.
106. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discovery Today 2003; 24: 1112-1120.
107. Chen J, Tung CH, Mahmood U, et al. in vivo Imaging of proteolytic activity in atherosclerosis. Circulation 2002; 105: 2766-2771.
108. Jain KK. Nanodiagnostics: Application of nanotechnology in molecular diagnostics. Expert Rev Mol Diagn 2003; 3: 153-161.
109. Gao XR, Dave SR. Quantum dots for cancer molecular imaging. Adv Exp Med Biol 2007; 620: 57-73.
110. Karwa A, Papazoglou E, Pourrezaei K, Tyagi S, Murthy S. Imaging biomarkers of inflammation in situ with fun ctionalized quantum dots in the dextran sodium sulfate (DSS) model of mouse colitis. Inflamm Res 2007; 56(12): 502-510.
111. Cai W, Chen X. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc 2008; 3(1): 89-96.
112. Carion O, Mahler B, Pons T, Dubertret B. Synthesis, encapsulation, purification and coupling of single quantum dots in phospholipid micelles for their use in cellular and in vivo imaging. Nat Protoc 2007; 2(10): 2383-2390.
113. Hamilton AJ, Huang SL, Warnick D, et al. Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol 2004; 43(3): 453-460.
114. Zheng J, Perkins G, Kirilova A, Allen C, Jaffray DA. Multimodal contrast agent for combined computed tomography and magnetic resonance imaging applications. Invest Radiol 2006; 41(3): 339-348.
115. Hiller KH, Waller C, Nahrendorf M, Bauer WR, Jakob PM. Assessment of cardiovascular apoptosis in the isolated rat heart by magnetic resonance molecular imaging. Mol Imaging 2006; 5(2): 115-121.
116. Schmitz SA, Coupland SE, Gust R, et al. Superparamagnetic iron oxide-enhance MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 2000; 35(8): 460-471.
117. Dijkgraaf I, Rijnders AY, Soede A, et al. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimezs via 1,3-dipolar cycloaddition and their biological evaluation: Implications for tumor targeting and tumor imaging purposes. Org Biomol Chem 2007; 5(6): 935-944.
118. Wu G, Yang W, Barth RF, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin Cancer Res 2007; 13(4): 1260-1268.
119. Langereis S, De Lussanet Qg, Van Genderen Mh, et al. Evaluation of d(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed 2006; 19(1): 133-141.
120. Kobayashi H, Kawamoto S, Saga T, et al. Avidin-dendrimer-(1B4M-Gd)(254): A tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. Bioconjug Chem 2001; 12(4): 587-593.
121. Wang SJ, Brechbiel M, Wiener EC. Characteristics of a new MRI contrast agent prepared from polypropyleneimine dendrimers, generation 2. Invest Radiol 2003; 38(10): 662-668.
122. Hartman KB, Laus S, Bolskar RD, et al. Gadonanotubes as ultrasensitive pH-smart probes for magnetic resonance imaging. Nano Lett 2008.
123. Singh R, Pantarotto D, Lacerda L, et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci USA 2006; 103(9): 3357-3362.
124. Richard C, Doan BT, Beloeil JC, Bessodes M, Tóth E, Scherman D. Noncovalent functionalization of carbon nanotubes with amphiphihic Gd(3+) chelates: Toward powertul T(1) and T(2) MRI contrast agents. Nano Lett 2008; 8(1): 232-236.
125. Su CH, Sheu HS, Lin CY, et al. Nanoshell magnetic resonance imaging contrast agents. J Am Chem Soc 2007; 129(7): 2139-2146.
126. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003; 100(23): 13549-13554.
127. Sutton LR, Donaubauer WA, Hampel F, Hirsch A. Tris(thioacetals) from benzene hexathiol: Towards covalent self-assembly. Chem Commun (Camb) 2004; 15: 1758-1759.
128. Wang Y, Da S, Kim MJ, et al. Ultrathin "Bed-of-Nails" Membranes of Single-Wall Carbon Nanotubes. J Am Chem Soc 2004; 126: 9502-9503.
129. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008; 117: 379-387.
130. Kircher MF, Allport JR, Graves EE, et al. in vivo High resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 2003; 63: 6838-6846.
131. Loo C, Lin A, Hirsch L, et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat 2004; 3: 33-40.
132. Litovsky S, Madjid M, Zarrabi A, Casscells SW, Willerson JT, Naghavi M. Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: Enhancement by tissue necrosis factor-α interleukin-1β, and interferon-γ. Circulation 2003; 107: 1545-1549.
133. Magnani, M., Antonelli, A.: GB2439747 (2008).
134. Magnani, M., Antonelli, A.: WO08003524 (2008).
135. Matsunaga, T.O., Dayton, P., Ferrara, K.W., Zhao, S., Bloch, S.: WO07038249 (2007).
136. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identified inflammatory activation of cells in atherosclerotisis. Circulation 2006; 114: 1504-11.
137. Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem 2002; 13: 554-560.
138. Lim YT, Kim S, Nakayama A, Stott NE, Bawendi MG, Frangioni JV. Selection of quantum dot wavelengths for biomedical assays and imaging. Mol Imaging 2003; 2: 50-64.
139. Westedt U, Barbu-Tudoran L, Schaper AK, Kalinowski M, Alfke H, Kissel T. Deposition of nanoparticles in the arterial vessel by porous balloon catheters: Localization by confocal laser scanning microscopy and transmission electron microscopy. AAPS Pharm Sci 2002; 4: E41.
140. Mulder WJ, Strijkers GJ, Briley-Saboe KC, et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med 2007; 58: 1164-1170.
141. Mulder WJ, Griffioen AW, Strijkers GJ, Cormode DP, Nicolay K, Fayad ZA. Magnetic and fluorescent nanoparticles for multi-modality imaging. Nanomed 2007; 2: 307-324.
142. Hyafil F, Cornily JC, Feig JE, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007; 13: 636-641.
143. Banai S, Chorny M, Gertz SD, et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 2005; 26: 451-461.
144. Lanza GM, Adendschein DR, Yu X, et al. Molecular Imaging and targeted drug delivery with a novel, lighand-directed paramagnetic nanoparticle technology. Acad Radiol 2002; 9(suppl2): S330-S331.